Yersinia Diagnostics Market
Number of pages: 100 | Report Format: PDF | Published date: 16 March, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market size value in 2022 |
US$ 3.2 billion |
|
Revenue forecast in 2031 |
US$ 4.63 billion |
|
Growth Rate |
CAGR of 4.2% from 2023 to 2031 |
|
Base year for estimation |
2022 |
|
Forecast Period |
2023-2031 |
|
Historical Year |
2021 |
|
Segments covered |
Test, Technique, and Region |
|
Regional scope |
North America, Europe, Asia Pacific, and the Rest of the World (ROW) |
According to the deep-dive market assessment study by Growth Plus Reports, the global yersinia diagnostics market was valued at US$ 3.2 billion in 2022 and is expected to register a revenue CAGR of 4.2% to reach US$ 4.63 billion by 2031.
Market Fundamentals
Yersinia is a genus of gram-negative bacteria that can cause various diseases in humans and animals. The three main species of Yersinia that are known to cause disease in humans are Yersinia pestis, Yersinia enterocolitica, and Yersinia pseudotuberculosis. Yersinia pestis is responsible for causing the plague, a severe and often fatal disease that has caused epidemics throughout history. Yersinia enterocolitica and Yersinia pseudotuberculosis can cause gastrointestinal infections that may result in diarrhea, abdominal pain, and fever. There are various diagnostic tests available for Yersinia infections which also include growing Yersinia bacteria in culture media and identifying them using biochemical tests. Blood tests can be used to detect antibodies to Yersinia bacteria. This can be helpful in diagnosing past infections or in confirming a suspected diagnosis. PCR can detect the genetic material of Yersinia bacteria in samples such as blood, stool, or tissue. Imaging studies such as X-rays or CT scans may be used to help diagnose conditions such as pneumonic plague. Enzyme-linked immunosorbent assay (ELISA) is a type of blood test that can detect specific antibodies to Yersinia bacteria. Immunofluorescence tests use antibodies labeled with fluorescent dyes to detect Yersinia bacteria in tissue samples. The choice of diagnostic test will depend on the specific symptoms and suspected diagnosis of the patient.
[755675]
Market Dynamics
The global Yersinia diagnostics market is expected to experience moderate growth in the coming years. There are several drivers that are contributing to the growth of the global Yersinia diagnostics market. The incidence of yersiniosis has been increasing in recent years, which is driving demand for Yersinia diagnostics. According to the Centers for Disease Control and Prevention (CDC), Y. enterocolitica causes almost 117,000 illnesses, 640 hospitalizations, and 35 deaths in the United States every year. The development of new diagnostic technologies, such as PCR and ELISA, has improved the accuracy and speed of Yersinia diagnostics. This has also increased the demand for Yersinia diagnostics products and services. Governments around the world are investing in various programs to control the spread of infectious diseases, including yersiniosis. This has created a favorable environment for the growth of the Yersinia diagnostics market. Healthcare professionals are becoming more aware of the importance of early and accurate diagnosis of Yersinia infections. This is driving demand for Yersinia diagnostics products and services. Point-of-care testing (POCT) is becoming increasingly popular, as it allows for rapid diagnosis and treatment of infectious diseases.
However, the market may face some restraints that could impact its growth and development. The cost of Yersinia diagnostics tests is quite high, which may make it difficult for some healthcare facilities or individuals to afford them. Many individuals may not be aware of Yersinia infections and the importance of early detection and treatment. This lack of awareness could lead to lower demand for Yersinia diagnostics tests and slower growth of the market.
The global Yersinia diagnostics market has been analyzed from three perspectives: Test, Technique, and Region.
Yersinia Diagnostics Market by Test
[85444]
Based on tests, the global Yersinia diagnostics market has been segmented into ELISA, stool cultures, radioimmunoassay, CT scan, colonoscopy, and ultrasonography.
Stool culture accounts for the largest revenue share in the global Yersinia diagnostics market. Stool culture Yersinia diagnostics is a test that uses feces samples to culture the bacteria and obtains a diagnosis. The simplest way to find out is to use the stool culture. The test can be completed in 24 to 48 hours, depending on the lab technique employed, and results are typically available in less than 72 hours. Compared to other serological approaches, stool culture Yersinia diagnostics detects more than 90% of cases (such as ELISA or Tube Agglutination). This means that stool culture is especially helpful in cases where an infection has occurred far from a microbiology facility where these fast antibody testing techniques can be used.
On the other hand, the ELISA segment accounted for the second-largest revenue share in the global Yersinia diagnostics market. An enzyme-linked antibody reaction called an ELISA (enzyme-linked immunosorbent assay) involves a sample and a chemical that is being studied. The measurement of antigen concentration in solution is the goal of this test. Antibodies in the blood can be found using the ELISA lab test. Detecting these antibodies can suggest infection with the Yersinia bacterium. Nevertheless, because ELISA tests cannot identify living organisms, they are unable to tell if a patient has only recently become ill or has had this kind of illness for some time.
Yersinia Diagnostics Market by Technique
Based on technique, the global Yersinia diagnostics market has been segmented into DNA probes, PCR, immunoassay, monoclonal antibodies, and others.
PCR segment accounts for the largest revenue share in the global Yersinia diagnostics market. Polymerase chain reaction (PCR) is a powerful molecular technique used for the detection and identification of Yersinia species in clinical and environmental samples. Yersinia is a genus of gram-negative bacteria that can cause a range of diseases, including bubonic plague, enterocolitis, and sepsis. PCR can be used to amplify specific DNA sequences that are unique to Yersinia species, allowing for their rapid detection and identification. One commonly targeted sequence in Yersinia diagnostics is the 16S ribosomal RNA gene, which is highly conserved among bacteria and can be used to distinguish between different bacterial species. In addition to detecting Yersinia in clinical samples, PCR can also be used to identify virulence factors that are associated with pathogenicity, such as the Yersinia virulence plasmid (pYV) and the Yersinia outer membrane proteins (Yops).
The monoclonal antibodies segment is projected to record a high revenue CAGR in the global Yersinia diagnostics market. Monoclonal antibodies can be used in the diagnosis of Yersinia infections. Yersinia is a genus of gram-negative bacteria that includes Yersinia pestis, the causative agent of plague, and Yersinia enterocolitica, which can cause gastrointestinal disease. One application of monoclonal antibodies in Yersinia diagnostics is in the development of immunoassays for detecting the presence of Yersinia antigens or antibodies in patient samples. For example, monoclonal antibodies can be used in enzyme-linked immunosorbent assays (ELISAs) to detect Yersinia-specific antigens or antibodies in serum, plasma, or other clinical samples. These assays can provide rapid and accurate diagnoses of Yersinia infections, allowing for early treatment and better patient outcomes.
Yersinia Diagnostics Market by Region
Based on region, the global Yersinia diagnostics market has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America accounts for the largest revenue share in the global Yersinia diagnostics market. This is attributed to the well-established healthcare infrastructure, sophisticated diagnostics, etc. U.S. accounts for the largest revenue share in the regional market. The Yersinia diagnostics market in the United States is primarily driven by the increasing prevalence of Yersinia infections, which can cause a range of diseases including Yersiniosis, plague, and gastroenteritis. The market is expected to continue growing due to the rising demand for accurate and rapid diagnostic tests for Yersinia infections. In the US, infections causing gastroenteritis are the second most common infection. The major players in the Yersinia diagnostics market in the US include companies like Bio-Rad Laboratories, Inc., Becton, Dickinson and Company, Thermo Fisher Scientific, Inc., and QIAGEN N.V., among others. These companies offer a range of diagnostic products, including immunoassays, PCR kits, and microbial identification systems for the detection of Yersinia infections. In addition to these established players, there is also a growing number of smaller companies and startups focused on developing innovative Yersinia diagnostic technologies, such as rapid point-of-care tests and next-generation sequencing platforms. Overall, the Yersinia diagnostics market in the U.S. is expected to continue growing in the coming years, driven by factors such the need for more accurate and rapid diagnostic tests, and ongoing technological advancements in the field of diagnostic testing.
The Yersinia diagnostics market in the Asia Pacific region is expected to experience significant growth over the forecast period. The market is driven by factors such as increasing incidence of yersinia infections, rising awareness about the disease, and increasing healthcare expenditure in the region. The market is segmented on the basis of diagnostic methods, including traditional methods and molecular diagnostics. Traditional methods such as culture and serology are widely used in the region, but molecular diagnostics are expected to gain popularity due to their higher accuracy and sensitivity. China and India are expected to be the major contributors to the market growth due to their large population base and increasing healthcare expenditure.
Competitive Landscape
Some of the prominent players operating in the global yersinia diagnostics market are:
Strategic Developments
The global yersinia diagnostics market is expected to grow at a revenue CAGR of 4.2% in the forecast period.
Abbott Laboratories, Bio-Rad Laboratories, GlaxoSmithKline plc, Danaher Corporation, and Merck KGaA are a few key players in the global yersinia diagnostics market.
The ELISA segment yersinia diagnostics segment has the largest revenue share in the global yersinia diagnostics market.
Asia Pacific region is expected to observe the highest global yersinia diagnostics market growth in the forecast period.
The global yersinia diagnostics market was valued at US$ 3.2 billion in 2022
*Insights on financial performance are subject to the availability of information in the public domain
Using the fundamental research and knowledge services capabilities of GRG Health, Growth Plus Reports may now be tailored based on client needs.
GRG Health's unique GrowthMIX strategy and comprehensive research methodology enable us to provide unique and valuable insights to our clients while uncovering trends that would not be discovered using traditional techniques.
Snehal Deshmukh
Principle Consultant
Speak to analyst